<DOC>
	<DOC>NCT00908531</DOC>
	<brief_summary>The hypothesis to be addressed in this randomized phase III trial is that 4 months of letrozole may be superior to surgery as primary therapy for early stage hormone receptor positive breast cancer in postmenopausal women, provided that these patients will receive definitive and radical surgery and adjuvant therapies as otherwise indicated at the completion of preoperative letrozole.</brief_summary>
	<brief_title>Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Informed consent Age 60 years or older Measurable nonmetastatic and noninflammatory breast cancer Tumor of 2 cm or larger ER and/or PgR positive tumor Comorbidity index 0 3, e.g., no other serious medical condition Prior medical therapy for a malignant disease, including aromatase inhibitors Distant metastasis Need for chemotherapy Past or current history of other neoplasms (except for curative treated basal skin cancer or in situ carcinoma of the cervix uteri) Treatment with a nonapproved drug within 30 days</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Breast neoplasms</keyword>
	<keyword>Randomised trial</keyword>
	<keyword>Aromatase Inhibitors</keyword>
	<keyword>Preoperative care</keyword>
	<keyword>Age 60 or older</keyword>
	<keyword>Hormone receptor positive tumor</keyword>
	<keyword>Tumor lager than 2 cm</keyword>
	<keyword>No distant metastasis</keyword>
</DOC>